RxDoctor Payments DataLook up a doctor →

Steve Lin, MD

Interventional Cardiology · Lexington, KYNPI 1518979111

Payments from drug & device makers

$372,064in general payments, 2019–2025

Across 878 payments — averaging $423.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$251K
  • Boehringer Ingelheim$40K
  • Johnson & Johnson$28K
  • Lilly USA, LLC$15K
  • Novartis$10K
  • AstraZeneca$10K
  • plus $19K from 41 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$372,064 in reported general payments places this provider in the 95th percentile of 129 interventional cardiology providers in Kentucky.

See all interventional cardiology providers in Kentucky

Medicare billing

Part B allowed, 2024
$239,058
Medicare patients
1,270
Services billed
4,541

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other interventional cardiology in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →